Amicus Therapeutics — FY2024 Earnings Presentation
25 slides from Amicus Therapeutics's earnings presentation, Feb 19, 2025
Slide 1: FY24 Results Conference Call & Webcast
AT T H E F O R E F R O N T O F THERAPIES FOR RARE DISEASES FY24 Results Conference Call & Webcast February 19, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and c
Slide 3: A Rare Company
A Rare Company A unique story in biotech with significant revenue growth and profitability First Two- 10-15% First Oral $528M Component Therapy Precision for Pompe Disease Medicine for Fabry Disease FY 2025 2024 Total Revenue Galafold Revenue (+33% Growth)1 Growth1 65-85% FY 2024 Non-GAAP Leverageab
Slide 4: 2024 Results
2024 Results We closed 2024 with exceptional growth of 33% and strong momentum heading into 2025 FY 2024 Guidance Results Total Revenue Growth1 30% to 32% 33% Galafold Revenue Growth1 16% to 18% 19% Pombiliti + Opfolda Revenue1 $69M to $71M $70.2M Non-GAAP Operating Expense $340M to $350M $347.8M No
Slide 5: 2025 Strategic Priorities
2025 Strategic Priorities Deliver total revenue growth of 17-24% at CER1 Double-digit Galafold® revenue growth of 10-15% at CER1 Pombiliti®+ Opfolda® revenue growth of 65-85% at CER1 Advance ongoing studies to broaden labels and strengthen scientific leadership in Fabry and Pompe diseases Deliver po
Slide 6: Galafold Continued Growth
Galafold ® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 6
Slide 7: 2024 Galafold Success
2024 Galafold Success (as of December 31, 2024) Only approved oral treatment in Fabry disease and standard of care for amenable patients A unique mechanism of action for Fabry patients with amenable variants $458.1M FY24 Galafold Revenue 65% +19% Share of Treated FY24 Galafold Amenable Patients Grow
Slide 8: Galafold Performance
Galafold Performance FY 2024 Galafold reported revenue of $458.1M (+19% growth at CER) +10-15%1 Global mix of naïve (~60%) and switch $458M (~40%) patients2 $388M Q4 Expanding market through uptake in $128M naïve population as well as geographic $329M $306M and label expansion $261M Q3 $120M M
Slide 9: Improving Diagnosis of Fabry Disease
Improving Diagnosis of Fabry Disease Multiple initiatives leveraging AI and family screening to improve diagnosis of Fabry disease Collaboration using AI to diagnose Fabry Collaboration for change in health disparity Initial findings from Fabry pilot programs in U.K. – Minority and low-income grou
Slide 10: Pombiliti + Opfolda
Pombiliti® (cipaglucosidase alfa-atga) + ® Opfolda (miglustat) Potential to establish a new standard of care for people living with late-onset Pompe disease 10
Slide 11: Pombiliti + Opfolda Performance
Pombiliti + Opfolda Performance Successful first full year of launch in the U.S., Germany, Austria, Spain and the U.K. Annual Revenue 2024 Geographic Mix $70.2M Q4 $22M Q3 U.S. $21M Ex-U.S. 43% 57% Q2 $11.6M $16M Q1 $11M FY23 FY24 11 1 CER: Constant Exchange Rates
Slide 12: Pombiliti + Opfolda Global Launch Metrics
Pombiliti + Opfolda Global Launch Metrics ~220 individuals treated or scheduled provides strong foundation for 2025 Global Launch: Individuals Treated or Scheduled ~220 • ~220 patients have been treated or scheduled to be treated with commercial product – ~209 treated patients – ~25 new prescription
Slide 13: Pombiliti + Opfolda Growth Drivers
Pombiliti + Opfolda Growth Drivers Amicus focused on key drivers of growth in 2025 Pombiliti + Opfolda Revenue +65-85%1 Increasing number of net new patients Increasing depth and breadth of prescribers $70M Expect to launch in up to 10 new countries throughout 2025 Continuing to drive differ
Slide 14: Geographic Expansion
Geographic Expansion 3 new regulatory approvals and up to 10 new launch countries in 2025 Regulatory Regulatory approvals anticipated in 2025: Recently approved in Australia Regulatory approvals in Canada and Japan also anticipated in 2025 CANADA AUSTRALIA JAPAN Combined ~150-200 people 18+ livi
Slide 15: Ongoing Clinical Studies
Ongoing Clinical Studies Continuing to build the body of evidence to support planned label expansion Clinical study in children with late-onset Pompe disease (LOPD) Clinical study in children with infantile-onset Pompe disease (IOPD) Amicus registry adding to evidence on differentiated MOA and long-
Slide 16: WORLDSymposium 2025
WORLDSymposium 2025 TM Strong presence at WORLDSymposium demonstrating leadership in Fabry and Pompe diseases • 2 platform and 20 poster presentations • Expanding our real-world evidence of Galafold with high utility • Further evidence supporting use of Pombiliti + Opfolda • Significant conference f
Slide 17: Corporate Outlook
Corporate Outlook Delivering on our mission for patients and shareholders 17
Slide 18: FY 2024 Select Financial Results
FY 2024 Select Financial Results FY 2024 revenue of $528M, up 32% and non-GAAP net income of $73.9M Q4 Full Year (in thousands, except per share data) Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Net product sales $ 149,706 $ 115,082 $ 528,295 $ 399,356 Cost of goods sold 14,836 11,324 52
Slide 19: Full-Year 2025 Financial Guidance
Full-Year 2025 Financial Guidance FY 2025 Financial Guidance1 2025 Total Revenue Growth1 17% to 24% Galafold Revenue Growth1 10% to 15% FY 2025 Revenue Sensitivity Given the proportion of Amicus revenue ex-US Pombiliti + Opfolda Revenue Growth1 65% to 85% (~60% in 2024), a change in USD exchange rat
Slide 20: Distribution of Galafold Quarterly Sales
Distribution of Galafold Quarterly Sales Distribution of Galafold® Revenue by Quarter over Past 5 Years Q1 Q2 Q3 Q4 5 Year Avg. 22% 24% 26% 28% 20
Slide 21: A Rare Company
A Rare Company A unique story in biotech with significant revenue growth and profitability Surpassing $1B in Total Sales Double-digit in 2028 Leverageable Revenue Rare Disease Growth Infrastructure Self- Sustainable Two Approved Company and Therapies Growing Free Cash Flow 21
Slide 22: Appendix
Amicus Therapeutics Appendix
Slide 23: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures 23
Slide 24: Reconciliation of Non-GAAP Financial Measures (Cont’d)
Reconciliation of Non-GAAP Financial Measures (Cont’d) 24
Slide 25: Exchange Rates
Exchange Rates Q4 2024 Currency Average Rates FX Rates Q4 2023 Q4 2024 Variance USD/EUR 1.076 1.067 (0.8%) USD/GBP 1.241 1.282 3.3% USD/JPY 0.007 0.007 (3.0%) Year-End 2024 vs. Full-Year 2024 Currency Average Rates1 FX Rates Year-End 2024 Full-Year 2024 Variance USD/EUR 1.041 1.082 (3.8%) USD/GBP 1.